Clinical trial
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets…
NCT01335997 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT01335997 |
|---|---|
| Title | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) |
| Official title | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hypercholesterolemia, Mixed Dyslipidemia |
| Intervention type | Drug |
| Interventions | ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM), Placebo Run-In, SIM-matching placebo |
| Enrollment | 1,139 |
| Start date | May 1, 2011 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Apr 15, 2011 |
| Last update posted | Feb 6, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: